Brodalumab: Six-Year US Pharmacovigilance Report

By sjmartinez • November 27, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb). 2024 Nov 26. doi: 10.1007/s13555-024-01304-y. Epub ahead of print. PMID: 39589679.

Tags: Adverse events, Dermatology, Drug reaction, psoriasis, Publications, real-world, safety

Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT

Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, López Pinto JM, Wixted K, Thaçi D. Bimekizumab Impact[...]

Differences in Prescription Patterns Among Various Physician Specialties for Patients with Chronic Spontaneous Urticaria

Chou P, Ma E, Roberts A, Jeong C, Katz A, Yan MJ, Johnsen N, Nong Y, Yee M, Armstrong A. Differences in Prescription Patterns Among[...]

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

Armstrong AW, Warren RB, Sofen H, Spelman L, Linaberry M, Becker B, Jou YM, Daamen C, Kimball AB. Deucravacitinib in Plaque Psoriasis After Inadequate Response[...]